Mylan (NASDAQ:MYL) has agreed to acquire Aspen Pharmacare Holdings Limited’s thrombosis business in Europe for €641.9M to be paid in two tranches, €263.2M upfront and €378.7M on June 25, 2021.
Leading coagulants Arixtra, Fraxiparine, Mono-Embolex and Orgaran generated ~€231M in sales during the 12-month period ended June 30.
Aspen will continue to manufacture and supply product.
The transaction, expected to be finalized next quarter, should be immediately accretive to Viatris upon the completion of the Upjohn merger, also expected to be completed next quarter.
The deal should not impact its 2020 target of ~$1B of debt repayments or Viatris’ debt repayment and target leverage commitments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.